

Changes in PrCreon Minimicrospheres® 35 (pancreatin) capsule shell

Dear {{customText[Dr. | Mr. | Mrs. | Ms. |]}} {{acclName}},

Viatriis is committed to providing access to safe and reliable medicines to our patients.

We would like to inform you of the change in colour of Creon 35 capsules from reddish brown to burnt orange. This change should not affect the quality, safety, or efficacy of the treatment.

Creon 35 Lot 64719 was the first batch released in Canada on May 22, 2024 with this new colour.

If you have any questions, please contact Viatriis Customer Service at 1-800-575-1379 or email customerservice.ca@viatriis.com. For medical information requests, please call 1-877-446-3679.

Creon Minimicrospheres® (pancreatin) is indicated in pediatric and adult patients for: the treatment of pancreatic exocrine insufficiency attributed to cystic fibrosis, chronic pancreatitis, or any other medically defined pancreatic disease that might require pancreatic enzyme therapy. Consult the Product Monograph at <https://healthproducts.canada.ca/dpd-bdpp/index-eng.jsp> for more information about conditions of clinical use, contraindications, warnings, precautions, adverse reactions, interactions and dosing. The Product Monograph is also available by calling BGP Pharma ULC at 1-877-446-3679.

Yours Sincerely,

Viatriis Canada

Adverse events should be reported immediately to Viatriis by phone 1-877-446-3679 or e-mail PV.Canada@viatriis.com or to Health Canada by visiting the web page on [Adverse Reaction Reporting](#) or by calling toll-free at 1-866-234-2345.

CA-CRE-2024-00001B - JN2024